AKAN
Akanda Corp
NASDAQ · Pharmaceuticals
$0.96
+0.06 (+6.34%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 777.7K | 707.3K | 858.5K |
| Net Income | 128.9K | 94.3K | 103.5K |
| EPS | — | — | — |
| Profit Margin | 16.6% | 13.3% | 12.1% |
| Rev Growth | -2.7% | +7.8% | +11.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 623.9K | 606.2K | 721.3K |
| Total Equity | 1.34M | 1.23M | 1.39M |
| D/E Ratio | 0.46 | 0.49 | 0.52 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 197.3K | 212.4K | 232.8K |
| Free Cash Flow | 80.3K | 76.9K | 86.9K |